Hepatology Research

Article	Citations
MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: Generalized estimating equation approach	100
Liver injury is associated with severe coronavirus disease 2019 (COVID‐19) infection: A systematic review and meta‐analysis of retrospective studies	96
Evidence‐based clinical practice guidelines for liver cirrhosis 2020	86
Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 update	61
Japan Society of Hepatology guidelines for the management of hepatitis C virus infection: 2019 update	59
Longitudinal changes of liver function and hepatitis B reactivation in COVID‐19 patients with pre‐existing chronic hepatitis B virus infection	59
Evidence‐based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020	57
MAFLD: Renovation of clinical practice and disease awareness of fatty liver	53
Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis	45
Report of the 22nd nationwide follow‐up Survey of Primary Liver Cancer in Japan (2012–2013)	41
Modelling the economic and clinical burden of non‐alcoholic steatohepatitis in East Asia: Data from Hong Kong	37
Multicenter prospective study of stereotactic body radiotherapy for previously untreated solitary primary hepatocellular carcinoma: The STRSPH study	36
Reduced handgrip strength predicts poorer survival in chronic liver diseases: A large multicenter study in Japan	36
Report of the 21st Nationwide Follow‐up Survey of Primary Liver Cancer in Japan (2010–2011)	34
Comparative analysis of liver functional reserve during lenvatinib and sorafenib for advanced hepatocellular carcinoma	32
Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH‐HCC Guidelines)	32
Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child‐Pugh class A or B liver function in real‐world clinical practice	31
Accuracy of the Enhanced Liver Fibrosis test, and combination of the Enhanced Liver Fibrosis and non‐invasive tests for the diagnosis of advanced liver fibrosis in patients with non‐alcoholic fatty li	30
Lenvatinib versus Sorafenib as first‐line treatment in hepatocellular carcinoma: A multi‐institutional matched case‐control study	30
Diagnostic accuracy of FibroScan‐AST score to identify non‐alcoholic steatohepatitis with significant activity and fibrosis in Japanese patients with non‐alcoholic fatty liver disease: Comparison betw	30
Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria	29
Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy	29
Clinical and anthropometric characteristics of non‐obese non‐alcoholic fatty liver disease subjects in Japan	28
Attenuation imaging based on ultrasound technology for assessment of hepatic steatosis: A comparison with magnetic resonance imaging‐determined proton density fat fraction	27
Hepatocellular carcinoma after Fontan surgery: A systematic review	27

Analysis of the optimal psoas muscle mass index cut‐off values, as measured by computed tomography, for the diagnosis of loss of skeletal muscle mass in Japanese people	27
Clinicopathological characteristics of combined hepatocellular cholangiocarcinoma from the viewpoint of patient prognosis after hepatic resection: High rate of early recurrence and its predictors	27
Artificial intelligence/neural network system for the screening of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis	26
Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis	26
Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease	26
Incidence of microsatellite instability‐high hepatocellular carcinoma among Japanese patients and response to pembrolizumab	26
Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma	25
Immune microenvironment of hepatocellular carcinoma, intrahepatic cholangiocarcinoma and liver metastasis of colorectal adenocarcinoma: Relationship with histopathological and molecular classification	25
Association of coagulopathy with liver dysfunction in patients with COVID‐19	25
Exosome circCMTM3 promotes angiogenesis and tumorigenesis of hepatocellular carcinoma through miR‐3619‐5p/SOX9	23
Pathological characteristics of liver sinusoidal thrombosis in COVID‐19 patients: A series of 43 cases	23
Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC‐B stage patients classified as beyond up to seven criteria – Multicenter analysis	23
Strategy for advanced hepatocellular carcinoma based on liver function and portal vein tumor thrombosis	22
Comparison of therapeutic outcomes of sorafenib and lenvatinib as primary treatments for hepatocellular carcinoma with a focus on molecular‐targeted agent sequential therapy: A propensity score‐matche	22
Effect of pemafibrate on fatty acid levels and liver enzymes in non‐alcoholic fatty liver disease patients with dyslipidemia: A single‐arm, pilot study	21
JSH Guidelines for the Management of Hepatitis C Virus Infection, 2019 Update; Protective Effect of Antiviral Therapy against Hepatocarcinogenesis	20
Zinc deficiency predicts overt hepatic encephalopathy and mortality in liver cirrhosis patients with minimal hepatic encephalopathy	20
Calf and arm circumference as simple markers for screening sarcopenia in patients with chronic liver disease	20
Potential of ultra‐highly sensitive immunoassays for hepatitis B surface and core‐related antigens in patients with or without development of hepatocellular carcinoma after hepatitis B surface antigen	20
Treatment of hepatocellular carcinoma during the COVID‐19 outbreak: The Working Group report of JAMTT‐HCC	20
Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multic	19
Characteristics of hepatocellular carcinoma arising from Fontan‐associated liver disease	19
LINC02499, a novel liver‐specific long non‐coding RNA with potential diagnostic and prognostic value, inhibits hepatocellular carcinoma cell proliferation, migration, and invasion	19
Transarterial chemoembolization plus a PD‐1 inhibitor with or without lenvatinib for intermediate‐stage hepatocellular carcinoma	19
Artificial liver treatment improves survival in patients with hepatitis B virus‐related acute‐on‐chronic liver failure: A case‐control matched analysis	18
Myostatin as a fibroblast‐activating factor impacts on postoperative outcome in patients with hepatocellular carcinoma	18
Prevalence and characteristics of portopulmonary hypertension in cirrhotic patients who underwent both hepatic vein and pulmonary artery catheterization	18
Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria	18
Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis	17
Serum matrix metalloproteinase‐7 in biliary atresia: A Japanese multicenter study	17
Hepatocellular carcinoma and other complications of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in Japan: A structured review of published works	17
Usefulness of neutrophil‐to‐lymphocyte ratio in predicting progression and survival outcomes after atezolizumab–bevacizumab treatment for hepatocellular carcinoma	17
Real‐world efficacy and safety of 12‐week sofosbuvir/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection	17
Characterization of hepatitis B virus DNA integration patterns in intrahepatic cholangiocarcinoma	16
Easy albumin–bilirubin score as a new prognostic predictor in hepatocellular carcinoma	16
Usefulness of the Global Leadership Initiative on Malnutrition criteria to predict sarcopenia and mortality in patients with chronic liver disease	16
Lean/normal‐weight metabolic dysfunction‐associated fatty liver disease is a risk factor for reflux esophagitis	15
Therapeutic efficacy of lenvatinib as third‐line treatment after regorafenib for unresectable hepatocellular carcinoma progression	15
aMAP score prediction of hepatocellular carcinoma occurrence and incidence‐free rate after a sustained virologic response in chronic hepatitis C	15
Real‐world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus‐related decompensated cirrhosis	14
Liver disease in pregnancy	14
Association between the albumin–bilirubin (ALBI) score and severity of portopulmonary hypertension (PoPH): A data‐mining analysis	14
Clinical outcomes of direct‐acting antiviral treatments for patients with hepatitis C after hepatocellular carcinoma are equivalent to interferon treatment	14
Dysregulation of sphingolipid metabolic enzymes leads to high levels of sphingosine‐1‐phosphate and ceramide in human hepatocellular carcinoma	13
Impact of viral eradication by direct‐acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus‐related compensated cirrhosis patie	13
Non‐invasive diagnosis of non‐alcoholic steatohepatitis and advanced fibrosis in Japan: A targeted literature review	12
A novel rapid immunoassay of serum type IV collagen 7S for the diagnosis of fibrosis stage of nonalcoholic fatty liver diseases	12
Efficacy and safety of apararenone (MT‐3995) in patients with nonalcoholic steatohepatitis: A randomized controlled study	12
The stratification of cirrhosis	12
Comparison of diagnostic performance between FIB‐4 and NFS in metabolic‐associated fatty liver disease era	12

Two hepatectomy cases for initially unresectable hepatocellular carcinoma after achieving a radiological complete response to sequential therapy with lenvatinib and transcatheter arterial chemoemboliz	12
Non‐invasive fibrosis markers are associated with mortality risk in both general populations and non‐alcoholic fatty liver disease patients	12
Prospective study for an independent predictor of prognosis in liver cirrhosis based on the new sarcopenia criteria produced by the Japan Society of Hepatology	12
Novel strategies for the early diagnosis of hepatitis B virus reactivation	12
Effect of metabolic dysfunction‐associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: A nationwide study	12
Transarterial‐ chemoembolization remains an effective therapy for intermediate‐stage hepatocellular carcinoma with preserved liver function	12
Omics‐derived hepatocellular carcinoma risk biomarkers for precision care of chronic liver diseases	11
Comparison of stereotactic body radiotherapy and radiofrequency ablation for hepatocellular carcinoma: Systematic review and meta‐analysis of propensity score studies	11
Time‐dependent changes in the seroprevalence of COVID‐19 in asymptomatic liver disease outpatients in an area in Japan undergoing a second wave of COVID‐19	11
Prognosis of intrahepatic cholangiocarcinoma stratified by albumin–bilirubin grade	11
Portal hemodynamic effects of lenvatinib in patients with advanced hepatocellular carcinoma: A prospective cohort study	11
Mortality of inactive hepatitis B virus carriers in Japan is similar to that of the general population	10
Effects of a low‐intensity resistance exercise program on serum miR‐630, miR‐5703, and Fractalkine/CX3CL1 expressions in subjects with No exercise habits: A preliminary study	10
Diagnostic criteria for acute‐on‐chronic liver failure and related disease conditions in Japan	10
Clinical course of hepatitis C virus‐positive patients with decompensated liver cirrhosis in the era of direct‐acting antiviral treatment	10
Proposal of Stroop test cut‐off values as screening for neuropsychological impairments in cirrhosis: A Japanese multicenter study	10
Management of portal hypertension based on portal hemodynamics	10
Response Evaluation Criteria in Cancer of the liver version 6 (Response Evaluation Criteria in Cancer of the Liver 2021 revised version)	10
Metabolomic/lipidomic‐based analysis of plasma to diagnose hepatocellular ballooning in patients with non‐alcoholic fatty liver disease: A multicenter study	10
Meta‐analysis of the effect of sodium–glucose cotransporter 2 inhibitors on hepatic fibrosis in patients with type 2 diabetes mellitus complicated with non‐alcoholic fatty liver disease	10
Identification of microRNA‐96‐5p as a postoperative, prognostic microRNA predictor in nonviral hepatocellular carcinoma	10
Novel artificial intelligent/neural network system for staging of nonalcoholic steatohepatitis	9
Risk of hepatocellular carcinoma after sustained virologic response in hepatitis C virus patients without advanced liver fibrosis	9
Effects of alcohol consumption on multiple hepatocarcinogenesis in patients with fatty liver disease	9
Randomized controlled study to examine the efficacy of hepatic arterial infusion chemotherapy with cisplatin before radiofrequency ablation for hepatocellular carcinoma	9
Does immune checkpoint inhibitor exhibit limited efficacy against non‐viral hepatocellular carcinoma?: A review of clinical trials	9
NBAS disease: 14 new patients, a recurrent mutation, and genotype–phenotype correlation among 24 Chinese patients	9
Effects of pemafibrate on primary biliary cholangitis with dyslipidemia	9
The beneficial impact of metabolic dysfunction‐associated fatty liver disease on lenvatinib treatment in patients with non‐viral hepatocellular carcinoma	9
Assessing liver stiffness with conventional cut‐off values overestimates liver fibrosis staging in patients who received the Fontan procedure	9
Screening for portopulmonary hypertension using computed tomography‐based measurements of the main pulmonary artery and ascending aorta diameters in patients with portal hypertension	8
Construction of a 13‐microRNA‐based signature and prognostic nomogram for predicting overall survival in patients with hepatocellular carcinoma	8
Treatment outcomes of stereotactic body radiation therapy using a real‐time tumor‐tracking radiotherapy system for hepatocellular carcinomas	8
Safety and efficacy of sorafenib followed by regorafenib or lenvatinib in patients with hepatocellular carcinoma	8
Real‐world hospital mortality of liver cirrhosis inpatients in Japan: a large‐scale cohort study using a medical claims database	8
The efficacy of rituximab treatment for antibody‐mediated rejection in liver transplantation: A retrospective Japanese nationwide study	8
2‐Step PLT16‐AST44 method: Simplified liver fibrosis detection system in patients with non‐alcoholic fatty liver disease	8
Management of hepatitis B virus (HBV) reactivation in patients with resolved HBV infection based on a highly sensitive HB core‐related antigen assay	8
Case of hepatitis B virus reactivation after ibrutinib therapy in which the patient remained negative for hepatitis B surface antigens throughout the clinical course	7
Comparison of embolic effect between water‐in‐oil emulsion and microspheres in transarterial embolization for rat hepatocellular carcinoma model	7
Thrombopoietin receptor agonist is more effective than platelet transfusion for chronic liver disease with thrombocytopenia, shown by propensity score matching	7
Single nucleus transcriptomics data integration recapitulates the major cell types in human liver	7
Metabolic dysfunction‐associated fatty liver disease directly related to liver fibrosis independent of insulin resistance, hyperlipidemia, and alcohol intake in morbidly obese patients	7
Metabolic dysfunction‐associated fatty liver disease and liver fibrosis: Prevalence and associated factors in the middle‐aged and older US population	7
Sequential therapy including regorafenib for unresectable hepatocellular carcinoma: Effect of early relative changes in hepatic functional reserve after regorafenib administration on prognosis	7
Hepatic stellate cell as a Mac‐2‐binding protein‐producing cell in patients with liver fibrosis	7
Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A comparative retrospective study	7
Hepatocellular adenoma, approximately half and predominantly inflammatory subtype, in 38 Japanese patients with several differences in age, gender, and clinical background factors from Western populat	7
Association of liver stiffness and steatosis with hepatocellular carcinoma development in patients with hepatitis C virus infection who received direct‐acting antiviral therapy and achieved sustained	7
Serum Gas6 and Axl as non‐invasive biomarkers of advanced histological stage in primary biliary cholangitis	7
The ursodeoxycholic acid response score predicts pathological features in primary biliary cholangitis	7
Association between dietary patterns and prognosis of hepatocellular carcinoma in the Guangdong liver cancer cohort study	7
Multicenter study on the consciousness‐regaining effect of a newly developed artificial liver support system in acute liver failure: An on‐line continuous hemodiafiltration system	7
Time‐course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis	7
Clinical practice guidelines for autoimmune hepatitis	7
Intranasal therapeutic vaccine containing HBsAg and HBcAg for patients with chronic hepatitis B; 18 months follow‐up results of phase IIa clinical study	7
Proposal for new sleep disorder criteria in patients with chronic liver disease: Influence of liver‐related complications	7
Changes in disease characteristics of primary biliary cholangitis: An observational retrospective study from 1982 to 2016	7
Favorable outcomes of surgical resection for extrahepatic recurrent hepatocellular carcinoma	7
Calculated body muscle mass as a useful screening marker for low skeletal muscle mass and sarcopenia in chronic liver disease	6
Chemical conversion of aged hepatocytes into bipotent liver progenitor cells	6
Ratio of von Willebrand factor antigen to ADAMTS13 activity is a useful biomarker for acute‐on‐chronic liver failure development and prognosis in patients with liver cirrhosis	6
Comparison of efficacy and safety of entecavir and switching from entecavir to tenofovir alafenamide fumarate in chronic hepatitis B: Long‐term effects from a prospective study	6
Serum levels of immunoglobulin M‐free inhibitors of macrophage/CD5L as a predictive and early diagnostic marker for nonalcoholic steatohepatitis‐associated hepatocellular carcinoma	6
Screening siRNAs against host glycosylation pathways to develop novel antiviral agents against hepatitis B virus	6
Prevalence of fatty liver and advanced fibrosis by ultrasonography and FibroScan in a general population random sample	6
Clinical implication of immune checkpoint inhibitor on the chronic hepatitis B virus infection	6
High fatty liver index is an independent predictor of ischemic heart disease during a 10‐year period in a Japanese population	6
Outcome of patients with acute liver failure awaiting liver transplantation in Japan	6
Time‐resolved 3D cine phase‐contrast magnetic resonance imaging (4D‐flow MRI) can quantitatively assess portosystemic shunt severity and confirm normalization of portal flow after embolization of larg	6
Donor‐dominant one‐way matching of human leukocyte antigen‐A/B/DR alleles predicts graft‐versus‐host disease following living donor liver transplantation	6
Accuracy of carbohydrate‐deficient transferrin as a biomarker of chronic alcohol abuse during treatment for alcoholism	6
Prognosis of patients with liver cirrhosis: A multi‐center retrospective observational study	6
Comparison of the efficacy and safety of conventional transarterial chemoembolization with and without drug‐eluting beads embolization for the treatment of unresectable large hepatocellular carcinoma	6
Angiopoietin‐like protein 4 deficiency augments liver fibrosis in liver diseases such as nonalcoholic steatohepatitis in mice through enhanced free cholesterol accumulation in hepatic stellate cells	6
Significant improvement in portal‐systemic liver failure symptoms and successful management of portal‐splenic venous hemodynamics by the combination of interventional radiology and pharmacotherapy	6
Biomarkers for predicting nucleos(t)ide analogs discontinuation and hepatitis B virus recurrence after drug withdrawal in chronic hepatitis B patients	5
Non‐malignant portal vein thrombosis in a cohort of cirrhotic patients: Incidence and risk factors	5
The utility of biomarkers in prognosis assessment of patients with acute liver failure	5
Impact of antiviral therapy on risk prediction model for hepatocellular carcinoma development in patients with chronic hepatitis B	5

The promise of radiotherapy for hepatocellular carcinoma	5
Metabolomic profiles of breath odor compounds for prognostic prediction in patients with acute‐on‐chronic liver failure: A pilot study	5
Atherosclerotic cardiovascular disease in non‐metabolic nonalcoholic fatty liver disease	5
Development and multicenter validation of FIB‐6: A novel, machine learning, simple bedside score to rule out liver cirrhosis and compensated advanced chronic liver disease in patients with chronic hep	5
Virologic analysis of tenofovir resistance in a patient with chronic hepatitis B experiencing viral breakthrough during combination treatment with tenofovir disoproxil fumarate and entecavir	5
Multicenter retrospective study of initial treatment outcome and feasibility of initiating dose reduction of cabozantinib in unresectable hepatocellular carcinoma	5
Immunoglobulin G4 (IgG4)‐related autoimmune hepatitis and IgG4‐hepatopathy: A histopathological and clinical perspective	5
Validation of the easy‐to‐use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib	5
Nucleoside/nucleotide analog consolidation therapy in hepatitis B e‐antigen positive chronic hepatitis B patients: Three years should be preferred	5
Preoperative serum brain‐derived neurotrophic factor as a predictive biomarker for sepsis after living‐donor liver transplantation	5
LncRNA FGD5‐AS1 enhances the proliferation and stemness of hepatocellular carcinoma cells through targeting miR‐223 and regulating the expression of ECT2 and FAT1	5
Twelve weeks of ledipasvir/sofosbuvir all‐oral regimen for patients with chronic hepatitis C genotype 2 infection: Integrated analysis of three clinical trials	5
Significance of zinc deficiency in patients with hepatocellular carcinoma undergoing hepatic resection	5
Ramucirumab in patients with advanced hepatocellular carcinoma and elevated α‐fetoprotein: Outcomes by treatment‐emergent ascites	5
Postoperative direct‐acting antiviral treatment after liver resection in patients with hepatitis C virus‐related hepatocellular carcinoma	5
Circular ribonucleic acid nei‐like deoxyribonucleic acid glycosylase 3 governs the microribonucleic acid ‐3150b‐3p/laminin subunit gamma 1 network to partially promote the development of hepatocellula	5
Validation of albumin, bilirubin, and platelet criteria for avoiding screening endoscopy in patients with advanced fibrosis	5
Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using real‐world data	5
Spleen stiffness in patients with chronic liver disease evaluated by 2‐D shear wave elastography with ultrasound multiparametric imaging	5
The association of histological progression with biochemical response to ursodeoxycholic acid in primary biliary cholangitis	5
Pancreas stiffness in liver cirrhosis is an indicator of insulin secretion caused by portal hypertension and pancreatic congestion	5
Hypofractionated radiotherapy for hepatocellular carcinomas adjacent to the gastrointestinal tract	5
Furosemide as a factor to deteriorate therapeutic efficacy of tolvaptan in patients with decompensated cirrhosis	5
Indications and waiting list priority for deceased donor liver transplantation in HIV/HCV co‐infected hemophilic patients in Japan through contaminated blood product	4
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib	4
Effect of three or more treatments with lusutrombopag in patients with cirrhotic thrombocytopenia: A retrospective single‐center study	4
Optimal management of lenvatinib therapy for patients with unresectable hepatocellular carcinoma by balancing the therapeutic effect with the relative dose intensity	4
Usefulness of virtual parenchymal perfusion software visualizing embolized areas to determine optimal catheter position in superselective conventional transarterial chemoembolization for hepatocellula	4
Histopathological analysis of autoimmune hepatitis with “acute” presentation: Differentiation from drug‐induced liver injury	4
Is platelet monitoring during 7‐day lusutrombopag treatment necessary in chronic liver disease patients with thrombocytopenia undergoing planned invasive procedures? A phase IIIb open‐label study	4
An improved method to assess skeletal muscle mass in patients with liver cirrhosis based on computed tomography images	4
The neutrophil‐to‐lymphocyte ratio at the start of the second course during atezolizumab plus bevacizumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A mu	4
Efficacy and safety of raltitrexed‐based transcatheter arterial chemoembolization for intermediate and advanced hepatocellular carcinoma: A multicenter real‐world study	4
Serum angiopoietin‐2 levels predict regression of Mac‐2 binding protein glycosylation isomer‐based liver fibrosis after hepatitis C virus eradication by direct‐acting antiviral agents	4
Diagnostic accuracy of enhanced liver fibrosis test for nonalcoholic steatohepatitis‐related fibrosis: Multicenter study	4
Mac‐2 binding protein glycan isomer as noninvasive tool to assess liver fibrosis in children with chronic liver disease	4
Renal safety and biochemical changes for 2 years after switching to tenofovir alafenamide from long‐term other nucleotide analog treatment in patients with chronic hepatitis B	4
Reevaluation of Makuuchi’s criteria for resecting hepatocellular carcinoma: A Japanese nationwide survey	4
Predictors associated with a better response to the Japanese aluminum‐free hepatitis A vaccine, Aimmugen®, for people living with HIV	4
Carbon ion radiotherapy for patients with hepatocellular carcinoma in the caudate lobe	4
Response to crizotinib in a patient with MET‐amplified hepatocellular carcinoma	4
The imbalance between NKG2A and NKG2D expression is involved in NK cell immunosuppression and tumor progression of patients with hepatitis B virus‐related hepatocellular carcinoma	4
Liver fibrosis improvement assessed by magnetic resonance elastography and Mac‐2‐binding protein glycosylation isomer in patients with hepatitis C virus infection receiving direct‐acting antivirals	4
Impact of antiviral therapy for disease progression and non‐invasive liver fibrosis index in patients with chronic hepatitis C: Markov chain model analysis	4
Clinical outcomes of antithrombin III‐based therapy for patients with portal vein thrombosis: A retrospective, multicenter study	4
Measurement of multiple spleen lengths is not necessary for non‐invasive prediction of high‐risk esophagogastric varices	4
Overestimated renal function in patients with liver cirrhosis predicts poor prognosis	4
Synthesized HMGB1 peptide prevents the progression of inflammation, steatosis, fibrosis, and tumor occurrence in a non‐alcoholic steatohepatitis mouse model	4
Atherosclerotic cardiovascular disease risk difference in metabolic dysfunction‐associated fatty liver disease and nonalcoholic fatty liver disease	4
Phase I study of a novel therapeutic vaccine as perioperative treatment for patients with surgically resectable hepatocellular carcinoma: The YCP02 trial	4
Impact of hepatitis C virus on survival in patients undergoing resection of intrahepatic cholangiocarcinoma: Report of a Japanese nationwide survey	4
Analysis of drug‐induced liver‐related adverse event trend reporting between 1997 and 2019	4
Geriatric nutritional risk index as an easy‐to‐use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab	4
Efficacy of rifaximin, a poorly absorbed rifamycin antimicrobial agent, for hepatic encephalopathy in Japanese patients	4
Mitochondrial fission in hepatocytes as a potential therapeutic target for nonalcoholic steatohepatitis	4
Prevalence of anti‐Hepatitis E antibodies and impact on disease severity in non‐alcoholic fatty liver disease	4
Long‐term prognosis of liver disease in patients with eradicated chronic hepatitis C virus: An analysis using a Markov chain model	4
Impact of body fat accumulation on metabolic dysfunction‐associated fatty liver disease and nonalcoholic fatty liver disease in Japanese male young adults	4
Alanine aminotransferase levels as therapeutic targets after nucleotide/nucleoside analog therapy in patient with chronic hepatitis B	4
Comparison of modified CEUS LI‐RADS with sonazoid and CT/MRI LI‐RADS for diagnosis of hepatocellular carcinoma	4
Severity of liver fibrosis using shear wave elastography is influenced by hepatic necroinflammation in chronic hepatitis patients, but not in cirrhotic patients	4
Validation of fatty liver index as a predictor of hepatic steatosis in Asian populations: Impact of alcohol consumption and sex	3
Validation of the FibroScan‐aspartate aminotransferase score by vibration‐controlled transient and B‐mode ultrasound elastography	3
Lean nonalcoholic fatty liver disease: Age‐dependent differences in pathology, prognosis, and liver‐related events	3
Determinants of the effectiveness of bezafibrate combined with ursodeoxycholic acid in patients with primary biliary cholangitis	3
Automated image analysis of keratin 7 staining can predict disease outcome in primary sclerosing cholangitis	3
Clinical features of chronic hepatitis B patients with lean nonalcoholic fatty liver disease	3
Effects of sodium glucose cotransporter 2 inhibitors and pioglitazone on FIB‐4 index in metabolic‐associated fatty liver disease	3
Pemafibrate for primary biliary cholangitis with dyslipidemia: A proposal of a new treatment from Japan	3
Multicenter, retrospective, cohort study shows platelet counts predict hepatocellular carcinoma development in patients with nonalcoholic fatty liver disease	3
Absence of large portal collateral vessels is associated with spontaneous improvement of cirrhotic portal vein thrombosis	3
Treatment algorithm for thrombocytopenia in patients with chronic liver disease undergoing planned invasive procedures	3
Efficacy of combining electric‐field and coronal‐plane imaging to obtain ultrasound–ultrasound fusion images in monopolar radiofrequency ablation for patients with liver cancer	3
Significance of serum IP‐10/CXCL10 measurement in predicting post‐direct acting antiviral treatment liver function in patients with HCV‐decompensated liver cirrhosis	3
Assessment of treatment options for patients with hepatitis C virus recombinant form 2k/1b	3
Deep sequencing analysis of serum hepatitis B virus‐RNA during nucleot(s)ide analogue therapy	3
Risk factors for relapse of autoimmune hepatitis in Japan: A nationwide survey	3
Carbon‐ion radiotherapy versus radiofrequency ablation as initial treatment for early‐stage hepatocellular carcinoma	3
Early changes in tubular dysfunction markers and phosphorus metabolism regulators as a result of switching from entecavir to tenofovir alafenamide fumarate nucleoside analog therapy for chronic hepati	3
Characteristics of patients aged over 75 years with hepatitis C virus infection treated with direct‐acting antivirals in Japan: Evidence based on the nationwide, real‐world database in Japan	3
Furosemide as a factor to deteriorate therapeutic efficacy of rifaximin in patients with decompensated cirrhosis	3
Validation of the utility of Agile scores to identify advanced fibrosis and cirrhosis in Japanese patients with nonalcoholic fatty liver disease	3
Clinical impact of the finger‐circle test in patients with liver diseases	3
A combination of hepatic encephalopathy and body mass index was associated with the point of no return for improving liver functional reserve after sofosbuvir/velpatasvir treatment in patients with he	3
Novel biomarkers of acute kidney injury in chronic liver disease: Where do we stand after a decade of research?	3
Navitoclax improves acute‐on‐chronic liver failure by eliminating senescent cells in mice	3
Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon‐lambda 3 induction in chronic hepatitis B patients	3
Acute exacerbation of hepatitis B with hepatic failure during the first trimester of pregnancy: Delivery of a healthy term baby after liver transplantation	3
Significant association between HLA‐B*35:01 and onset of drug‐induced liver injury caused by Kampo medicines in Japanese patients	3
Regulatory function of interferon‐inducible 44‐like for hepatitis B virus covalently closed circular DNA in primary human hepatocytes	3
The hemoglobin, albumin, lymphocyte, and platelet score is a prognostic factor for Child–Pugh A patients undergoing curative hepatic resection for single and small hepatocellular carcinoma	3
Initial treatment response to transarterial chemoembolization as a predictive factor for Child–Pugh class deterioration prior to refractoriness in hepatocellular carcinoma	3
Metabolic management after sustained virologic response in elderly patients with hepatitis C virus: A multicenter study	2
Anticoagulation against portal vein thrombosis reduces mortality and liver cirrhosis‐related complications: A propensity score‐matched study	2
Antithrombin attenuates the progression of hepatocellular carcinoma by regulating neutrophil/interleukin‐8 signaling	2